Fowl Adenovirus Serotype 8b (FAdV-8b) continues to pose a significant threat to the poultry industry, causing inclusion body hepatitis and severe economic losses. Nuevogenix is advancing CRISAdVac, a next-generation live attenuated vaccine candidate designed to address this challenge with precision and safety.
CRISAdVac is developed using CRISPR-based attenuation strategies, allowing targeted modification of viral genomes while preserving immunogenicity. Unlike conventional attenuation methods, this approach enables greater control, reproducibility, and safety.
Current development efforts include:
- Upscaling production in optimized cell culture systems
- Process optimization to enhance viral yield, stability, and consistency
- Comprehensive efficacy evaluation, including in vitro studies and in vivo trials in SPF and commercial broiler chickens
Preliminary findings demonstrate promising immune responses with a favorable safety profile, supporting CRISAdVac’s potential as a commercially viable poultry vaccine.
Nuevogenix welcomes investors, strategic partners, and industry collaborators to engage with the CRISAdVac technology, explore collaborative development, and discuss pathways toward large-scale manufacturing, regulatory approval, and market deployment.
CRISAdVac reflects Nuevogenix’s commitment to delivering precision-engineered vaccines that meet real-world industry needs.